Key result
Inhibition of prolactin secretion is a new treatment option for peripartum cardiomyopathy.
Why the study?
Does inhibition of prolactin secretion improve outcomes in peripartum cardiomyopathy?
Does inhibition of prolactin secretion improve outcomes in peripartum cardiomyopathy?
The text provides a citation for a discussion on inhibition of prolactin secretion as a new treatment option for peripartum cardiomyopathy.
Answers are grounded in this paper and cite their sources.
May support prolactin inhibition in peripartum cardiomyopathy; leaves open confirmation of benefit in randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jahns et al. (2009) studied this question. Inhibition of prolactin secretion is a new treatment option for peripartum cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: